**REFERENCE PUBLICATIONS**


**IMMUNOSCORE®** is included in the **ESMO** Clinical Practice Guidelines (ESMO 2020 Guidelines as well as PAN-Asian adapted ESMO Guidelines 2021 for Localised Colon Cancer)

The **IMMUNOSCORE®** and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA.

**IMMUNITY ASSESSED, TREATMENT PERSONALIZED**

Guide your therapeutic strategy and patient discussion with accurate information based on immune response.
By providing an accurate measurement of T lymphocyte infiltration into the tumor, IMMUNOSCORE® gives healthcare providers insight into the risk of relapse.

**Designed to deliver critical information to guide chemotherapy decision-making, IMMUNOSCORE® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in stage III colon cancer to better inform on optimal FOLFOX treatment duration. Recently included within ESMO guidelines, IMMUNOSCORE® predicts the risk of relapse in patients with localized colon cancer.**

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pagès et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

**How can IMMUNOSCORE® help patient with localized colon cancer management?**

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

**Add resolution to your traditional risk assessment tools**

 Clinico-pathological parameters plus IMMUNOSCORE®

- Type of cancer
- Sex
- Stage
- Differentiation
- Mucinous (colloid)
- MSI
- LVI/PNI

IMMUNOSCORE® (High, Low)

**47% of prognosis is explained by IMMUNOSCORE®**

**A Clear Way Forward**

IMMUNOSCORE® can help patients and clinicians find more diagnostic clarity and get the actionable results needed to make better treatment decisions.

**Stage II Colon Cancer**

IMMUNOSCORE® can identify a large subset of patients (70%) that are classified as high-risk by TNM staging but whose actual risk of relapse is similar to that of low-risk patients. These patients can potentially be spared adjuvant chemotherapy and the associated toxicities.

70% of patients classified as clinically high risk actually have the same risk of relapse as low-risk patients when IMMUNOSCORE is High.

**Stage III Colon Cancer**

IMMUNOSCORE® informs about the optimal duration of FOLFOX treatment whatever the clinical risk, maximizing the benefit-risk balance by avoiding unnecessary exposure to chemotherapy associated toxicities.

50% of patients benefit the most from full chemotherapy duration

**IMMUNOSCORE® WORKFLOW**

IMMUNOSCORE® is available as a full service solution (performed at Veracyte CLIA laboratories).

**Tumor block or unstained slides**

Pathology lab

Patient post resection surgery

Veracyte labs

Report IMMUNOSCORE® results

10 working days after receipt of specimen

Stain & Scan Slides

**IMMUNOSCORE® can help patients and clinicians find more diagnostic clarity and get the actionable results needed to make better treatment decisions.**
By providing an accurate measurement of T lymphocyte infiltration into the tumor, IMMUNOSCORE® gives healthcare providers insight into the risk of relapse.

Designed to deliver critical information to guide chemotherapy decision-making, IMMUNOSCORE® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in stage III colon cancer to better inform on optimal FOLFOX treatment duration. Recently included within ESMO guidelines, IMMUNOSCORE® predicts the risk of relapse in patients with localized colon cancer.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

- Assessing patient’s recurrence risk
- Providing greater prognostic value than traditional measurements
- Guiding treatment decision and improves patients management

Add resolution to your traditional risk assessment tools

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pages et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.
REFERENCE PUBLICATIONS


IMMUNOSCORE® is included in the ESMO Clinical Practice Guidelines (ESMO 2020 Guidelines as well as PAN-Asian adapted ESMO Guidelines 2021 for Localised Colon Cancer)

The IMMUNOSCORE® and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA.

IMMUNITY ASSESSED, TREATMENT PERSONALIZED

Guide your therapeutic strategy and patient discussion with accurate information based on immune response

Contact us

Veracyte Labs FR
163 Avenue de Luminy - 13009 Marseille - FRANCE
P +33 (0)4 91 29 30 90
F +33 (0)4 91 29 30 99

Veracyte Labs VA
737 N 5th St, 6th Floor - Richmond, VA 23219 - USA
P +1 (804) 944-2000
F +1 (804) 533-1504

www.veracyte.com